Unlocking Orphan Neuromuscular Indications: Why IntraBio's Aqneursa Approval Signals a Regulatory Re-evaluation of Small-Cohort Crossover Trials
Dr. Dereck Mush, MD, MBA
IntraBio
Rare disease company behind Aqneursa, approved for ataxia in ataxia telangiectasia.
What they do
IntraBio develops modified amino acid therapeutics for rare neurodegenerative and lysosomal conditions. Its lead drug Aqneursa (levacetylleucine) won FDA approval in September 2026 for ataxia in patients with ataxia telangiectasia, following an earlier approval for Niemann Pick disease type C.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Rare neurology
- Product type
- Platform software
- Stage
- Growth
- Headquarters
- Austin, United States
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Transporter-Independent Pharmacology and the Orphan PRV Playbook
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBA